Chapter 46: Adult Oncological and Hematological Medications

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical treatment, there is this expectation of absolute precision.

Right.

It is almost like engineering.

If you have a bacterial infection, you give an antibiotic that targets that specific bacteria.

The doctor points to the lab result and says, there it is, problem solved.

And the collateral damage is, well, usually pretty minimal.

Yeah, it feels incredibly targeted, which is comforting, you know.

We like our medications to act like smart bombs, going exactly where they're supposed to go, fixing the problem and leaving everything else completely untouched.

But then you step into the world of oncology and hematology, pharmacology, and suddenly that precision machinery is, I mean, it is a whole different reality.

We are looking at a pharmacological landscape that is honestly aggressive.

That's the perfect word for it.

It is the absolute definition of a systemic battlefield.

Yeah.

And navigating that battlefield is exactly what we are mastering today.

Welcome to this deep dive.

If you are listening right now, it is just you, me, and our resident clinical expert.

Consider this your one -on -one high yield tutoring session.

We are using Chapter 46 from the Saunders Comprehensive Review for the NCLE -XRN examination as our battle map today.

So we are looking at oncological and hematological medications.

And our goal is to figure out not just what these drugs do, but how you as a nurse step in to manage the fallout.

We are going to build your clinical reasoning so that when you sit down for the NCLE -X, those priority decisions feel like second nature.

Exactly.

And to start, we really need to understand why this chapter groups oncological and hematological medications together in the first place.

I mean, it's all about cause and effect.

Lay it out for us.

Well, oncological medications, chemotherapy, are prescribed to treat the cancer.

But because of how they work, they severely damage the body's blood components.

So the hematological medications we will discuss are prescribed to rescue the patient from the side effects of those oncological drugs.

Oh, I see.

Yeah.

You really cannot safely administer the first without understanding how to save the patient with the second.

OK, let's unpack this.

Before we look at specific drug names, you need to understand the mechanism.

Like, how do these anti -neoplastic medications actually work against neoplastic or cancer cells?

Right.

So we have to look at the cell cycle.

Yeah.

The text breaks down the cell cycle.

I actually like to think of a cell dividing like a factory assembly line.

That is a great visual.

The cell cycle has distinct phases.

There is G1, where the cell gathers materials and prepares for division.

Then the S phase, where it synthesizes and completely doubles its DNA.

Got it.

Then G2, producing the specific proteins needed for division.

And finally, the M phase, or mycosis, where it physically splits into two cells.

Now, some chemotherapy medications are cell cycle phase specific.

They only attack the cell when it's on a very specific part of that assembly line.

Like targeting a specific machine in the factory.

Exactly.

And other medications are phase non -specific, meaning that they can destroy the cell at any point.

But here is the critical concept, and really the why, behind almost every side effect we are going to discuss today.

These medications do not perfectly discriminate between a bad cancer cell and a good normal cell, right?

Precisely.

The medications are designed to target rapidly dividing cells.

The problem is you have normal healthy cells in your body that also divide rapidly by nature, like your hair follicles, the lining of your gastrointestinal tract, and your bone marrow.

Because the drug cannot tell the difference between a dividing cancer cell and a dividing hair follicle cell.

Those normal cells are destroyed as collateral damage.

Wow.

Yeah.

That is the underlying mechanism behind why patients experience alopecia, or hair loss, severe nausea, and bone marrow suppression.

So if we are administering these incredibly powerful systemic drugs that wipe out healthy cells alongside the cancerous ones, how do we ensure we are giving the exact right amount?

I mean, we can't just guess.

No, we absolutely cannot.

Chemotherapy dosing is usually based on the patient's total body surface area, or BSA.

To calculate BSA accurately,

the nurse must have a current, accurate height and weight before each and every medication administration.

Wait, I want to push back on that for a second.

We are talking about cancer patients.

If a patient is actively vomiting for weeks from chemo or losing their appetite, their weight is going to be fluctuating wildly.

Are we really recalculating their dose every single time they walk into the clinic?

Can't we just look at their chart from last month?

That is exactly why you cannot rely on an old chart.

Relying on a previous weight or even just asking the patient to estimate their current weight is incredibly unsafe.

Oh, wow.

Yeah.

If they have lost 10 pounds and you give them a dose based on their weight from a month ago, you are now overdosing them with a highly toxic medication.

You must obtain those measurements yourself that day.

Which perfectly explains a classic clinical scenario the text poses.

If you look at practice question one, it asks about assessing a patient for optimal dosing.

You might be tempted to use their body mass index or maybe measure their abdominal girth, but those don't give you the total surface area.

No, they don't.

So the only safe, correct action is measuring the client's current weight and height yourself.

Exactly.

Because these medications are so devastating to normal cells, the nurse's priority immediately shifts from just administering the drug to aggressive monitoring and safety.

When chemotherapy causes the rapid destruction of massive amounts of cells, all that cellular debris has to go somewhere.

Right.

The cell breaks open and all its internal contents just dump into the bloodstream.

Yes.

And one of the most significant things released during that massive cell destruction is uric acid.

So if you are looking at lab values after a massive cell kill, a massive spike in uric acid is your red flag.

And this ties right into practice question 12 in the chapter.

The provider will often prescribe a medication called allopurinol specifically to lower that serum uric acid level and protect the patient.

Now let's connect this to the most critical safety issue we face, bone marrow suppression.

The bone marrow is the factory that produces your red blood cells, your platelets, and your white blood cells.

Okay.

When chemotherapy suppresses that factory, you see a dangerous drop in all three.

Let's look at the platelets first.

Our drop in platelets is called thrombocytopenia, which strips the patient of their ability to form blood clots.

Let's put some hard numbers to that because, you know, the NCLEX loves exact lab values and understanding the thresholds directly dictates your nursing actions.

Right.

So a normal platelet count is 150 ,000 to 450 ,000.

When the platelet count drops below 50 ,000, even minor trauma like bumping an arm or brightening teeth can lead to episodes of prolonged bleeding.

That is terrifying.

It gets worse.

If it drops below 20 ,000, the patient can experience spontaneous uncontrolled bleeding without any trauma at all.

A common trap a lot of nurses fall into in these clinical scenarios, and you see this in practice question 15, is looking at other labs like ammonia levels or clotting times when trying to assess bleeding risk in these patients.

But that's just a distraction.

If you see normal clotting times, but a platelet count sitting at 50 ,000, that 50 ,000 is the only number that should set off alarm bells.

It requires immediate bleeding precautions.

Next is the white blood cell drop, specifically neutropenia.

Neutrophils are the specific white blood cells that act as your first line of defense against bacterial infections.

The text teaches you how to calculate the absolute neutrophil count, or ANC, by multiplying the total white blood cell count by the percentage of neutrophils.

And what's the normal range for that?

A normal ANC is over a thousand.

And there is a massive take action protocol right here.

Imagine you are reviewing morning labs and you note your patient's ANC is 900.

What is your priority?

Well, an ANC of 900 means the patient has essentially no immune shield.

The nurse's clinical judgment must be to immediately withhold the scheduled chemotherapy infusion.

You cannot give them a drug that will further wipe out their bone marrow when their ANC is already below that 1 ,000 threshold.

That makes total sense.

Right.

You withhold the drug, notify the oncologist, and initiate strict neutropenic precautions to protect the patient from the outside world.

We are entirely focused on patient safety here, which makes sense.

But what about the nurse's safety?

I mean, we are talking about handling medications that are basically cellular poison.

These are severe biohazards.

They absolutely are.

The text is very clear that nurses who handle and administer these drugs face an increased risk of leukemia, adverse reproductive outcomes, and chromosomal damage.

Wow.

Yeah.

You must wear appropriate personal protective equipment, gloves,

gowns, eye protectors, and masks whenever there's a risk of exposure.

And importantly, nurses who are pregnant must avoid the preparation or administration of chemotherapy entirely.

So we have our PPE on.

We're administering the drug via an IV.

Let's talk about what happens if that toxic medication escapes the vein and leaks into the surrounding tissue.

That is called extravasation.

The text poses a great scenario in practice question 11.

Your patient complains of pain at the IV site, you look down and see redness and swelling, and you notice the infusion rate has slowed down.

If you see redness, swelling, and a slowed rate, you must immediately suspect extravasation.

Medication is leaking into the tissue and causing necrosis, literally eating away at Oh my gosh.

The test -taking strategy here is to visualize the situation and aggressively avoid actions that cause further damage.

Step one, immediately stop the infusion.

Step two, notify the primary health care provider.

Step three, prepare to apply heat or ice depending on the specific drug.

And step four, prepare to administer a prescribed antidote directly into the site.

I want to highlight something crucial here.

Some nurses might think, oh, the line is just a little sluggish, I'll increase the flow rate to flush it out.

Why is that so catastrophic?

Because if the vein is blown and the fluid is leaking into the tissue,

increasing the flow rate just violently pushes more tissue to strung poison directly into the patient's arm.

And similarly, you never restart the IV at a distal part of that same vein because the drug will just leak out of the hole you just made higher up.

Here's where it gets really interesting though.

Sometimes the danger isn't just local tissue damage on the arm, it is a massive systemic allergic reaction.

The text outlines a critical take -action protocol for anaphylaxis.

Imagine a 35 -year -old client receiving a drug like Paclitaxel who suddenly clutches their chest complaining of shortness of breath, dizziness, and severe itching.

That is a life -threatening, acute allergic response.

The priority cascade here is rigid and you must know it.

Step one, stop the medication immediately.

Step two, contact the rapid response team and the oncologist.

Okay, stop med, call for help.

Right.

You then administer oxygen, raise the client's feet and legs to help support their rapidly dropping blood pressure, and maintain the IV access but switch it to normal saline.

Finally, prepare to administer emergency medications like epinephrine.

Wait, if we are stopping the medication, why are we switching the IV to normal saline instead of just pulling the IV out completely?

Excellent question.

If the patient is going into anaphylactic shock,

their blood vessels are collapsing.

If you pull that IV out, you will never get another one in.

You switch to normal saline to keep the vein open and flowing so you have a direct pathway to push the life -saving epinephrine.

So what does this all mean?

It means before we even look at a specific drug name, your mind has to be locked into this safety framework.

Now that the protocols are set, let's look at the specific medication classes.

We'll start with the cell cycle phase non -specific drugs.

These hit the cell no matter what phase of division it's in.

First up, alkylating medications.

Alkylating agents work by physically breaking the DNA helix, which shatters the cell's ability to replicate.

Two very common ones you will see are cyclophosphamide and ifosfamide.

I see these two drugs come up constantly and they both have this massive warning about a condition called hemorrhagic cystitis.

Break that down for me, what is actually happening in the bladder?

When cyclophosphamide is broken down by the body, it creates toxic macabalites.

Those metabolites travel down to the bladder and sit there, acting almost like an acid on the bladder wall, causing severe bleeding and inflammation.

That's the hemorrhagic cystitis.

Which explains exactly why the primary nursing instruction for a patient on cyclophosphamide and you see this in practice question 13, is to push copious amounts of fluid.

We are talking 2000 to 3000 milliliters daily.

Yeah, that's a lot of fluid.

You are literally trying to flush the bladder out so those toxic byproducts don't have time to sit there and cause damage.

You also monitor their urine for hematuria or blood.

Sometimes, a medication called mezna is given alongside afosfamide, specifically to protect the bladder lining.

Another alkylating agent to be aware of is bustlefan.

As you've discussed earlier regarding cellular destruction, bustlefan causes a massive increase in uric acid levels, which is something tested in practice question 3.

So that is your primary lab value to monitor.

Then we have cisplatin.

Cisplatin is a platinum compound.

Exactly.

Think of cisplatin as a heavy metal, because platinum is a heavy metal.

Heavy metals are notorious for accumulating in the delicate hair cells of the inner ear and the tiny filtering tubules of the kidneys.

Oh, that makes sense.

Which is exactly why your primary assessments here are checking for severe ototoxicity, meaning tinnitus or hearing loss and nephrotoxicity.

You must assess for dizziness, hearing changes, and monitor renal function closely.

We've seen how these nonspecific drugs trash the bladder and the ears.

Let's look at another nonspecific class, antitumor antibiotic medications.

These interfere with DNA and RNA synthesis.

So what does this all mean for patient assessment?

For these, your clinical reasoning needs to focus heavily on the ABC's airway breathing and circulation.

Let's look at airway breathing first with a drug called bleomycin.

Bleomycin is notorious for causing pulmonary toxicity.

It can cause interstitial pneumonitis that actually progresses to permanent pulmonary fibrosis.

So if a patient is receiving bleomycin and you are anticipating diagnostic studies, you use that ABC strategy.

You ignore cardiac distractors, like an echocardiogram, which is the exact scenario in practice question 2.

And you immediately select pulmonary function studies.

You have to be listening to their lung sounds, assessing for crackles or dyspnea.

Conversely, let's look at the C in ABC's circulation.

Medications like donorubicin, doxorubicin, and idorubicin are strongly associated with cardiotoxicity.

They directly damage the heart muscle, causing heart failure, cardiomyopathy, and ECG changes.

How does that manifest in a patient assessment?

If a patient is on donorubicin and you are auscultating their lungs and hear crackles, that isn't a lung problem.

This cuts into practice question 14.

That indicates the drug has caused heart failure and the failing heart is causing fluid to back up into the lungs.

The text also notes that a cardioprotective agent called dexoroxin may be given alongside doctorubicin specifically to act as a shield and reduce this cardiomyopathy.

Now, let's shift our focus to the cell cycle phase specific classes.

Instead of bombing the whole factory, think of these specific drugs like a tollbooth on a highway.

They don't blow up the whole road.

They just wait at one specific checkpoint in the cell cycle and destroy any cell trying to pass through it.

That's a great analogy.

Thanks.

We'll start with antimetabolite medications, which sit at the S -phase tollbooth where DNA synthesis occurs.

These drugs basically halt the synthesis of cell proteins starving the cell.

A major one is fluorosil.

When a patient is on fluorosil, you have to assess for signs of cerebellar dysfunction.

That means watching for dizziness, weakness, and ataxia, that complete loss of physical coordination.

Another massive antimetabolite is methotrexate.

Methotrexate causes severe photosensitivity, so patients must use sunscreen and wear protective clothing.

But the most important clinical point about methotrexate is that when it is given in large doses, it is highly toxic to healthy cells as well.

To prevent this fatal toxicity, the nurse was prepared to administer a drug called leukovorin.

This is universally known as a leukovorin rescue, right?

What exactly are we rescuing them from?

Well, methotrexate essentially starves cells by blocking folic acid.

Leukovorin acts as a rescue agent.

It is a form of active folic acid that bypasses the methotrexate block, swooping in to save the normal, healthy cells from toxicity while letting the chemo continue to kill the cancer.

Wow.

Next up are the mitotic inhibitor medications, also known as vinca alkaloids.

These act specifically at the M -phase toll booth to prevent mitosis or cell division.

A key drug here is vincristine.

What's fascinating here is how vincristine specifically targets the nervous system.

The NCLEX writers love testing on that unique feature, like in practice question 6.

If you are looking for an adverse effect specific to vincristine, it is peripheral neuropathy.

The text explains this manifests physically.

The drug damages nerve conduction, leading to numbness and tingling in the fingers and toes.

Sometimes the first sign is a depressed Achilles tendon reflex.

It can also cause flotosis -trooping eyelids and paralytic alias because the nerve is controlling the gut shutdown.

And this is where test -taking strategy comes in.

If you see distractors like hair loss or diarrhea, you have to recognize those are general side effects of almost all chemo.

Neuropathy is the specific red flag you are hunting for with vincristine.

Got it.

Also, a major safety point, the best practice for giving vincristine is IV piggyback via minibag, never ever IV push.

Finally, for the specific agents we have topoizomerase inhibitors, which act on the G2 and S phases to block enzymes needed for DNA synthesis.

A key medication here is edipocyte.

The text highlights a very specific scenario for edipocyte, which is also covered in practice question 4.

When you are administering it, you are monitoring for a sudden dangerous drop in blood pressure orthostatic hypotension.

To prevent the patient's blood pressure from completely tanking, edipocyte must be administered slowly over 30 to 60 minutes, and you have to monitor their blood pressure closely during the entire infusion.

If we connect this to the bigger picture, we've covered breaking the DNA, starving the cell of proteins, and stopping cell division at the toll booth.

But there are other ways to fight cancer that don't involve direct cellular poison.

That brings us to hormonal medications and immunomodulators.

Sometimes the goal is to alter the hormonal environment to slow the growth of hormone sensitive tumors.

The most famous example here is tamoxifen.

Tamoxifen is an anti -estrogen medication.

It competes with estrogen, binding to estrogen receptors.

It is prescribed specifically for metastatic breast carcinoma or to prevent breast cancer in high -risk patients.

So if a patient with bladder cancer asks if they can take it, the answer is no, which is practice question 8.

But here is the critical assessment piece.

From practice question 9, tamoxifen alters the hormonal environment, which can lead to a dangerous shift in electrolytes, specifically causing hypercalcemia.

Exactly.

You must monitor their calcium levels.

If the calcium levels spike, you have to watch for increased urine volume,

excessive thirst, and hypotonicity of the muscles.

Another hormonal medication is maestral acetate, a progestin.

You must contact the provider before giving maestral acetate if the patient has a history of venous thromboembolism, which relates to practice question 10 because this medication significantly increases the risk of dangerous blood clots.

We also have asparaginease, an enzyme.

The text warns, and practice question 7 reinforces, that asparaginease is strictly contraindicated if the patient has a history of pancreatitis because the drug directly impairs pancreatic function.

Then we have the immunomodulators, or biological response modifiers.

Instead of poisoning the cancer, these drugs stimulate the patient's own immune system to recognize and destroy the cancer cells.

Interleukins help immune cells destroy abnormal cells and interferons slow down tumor cell division.

The text also covers targeted therapy, like monoclonal antibodies.

These are the drugs ending in MAB, like rituximab or bevacizumab.

Because these are often derived from biological sources, the biggest adverse effect to watch out for is severe allergic reactions.

And remember that severe bone marrow suppression we talked about at the very beginning.

We finally arrive at the hematological medications used to treat that fallout.

We use colony stimulating factors, like filgrastem, to wake the bone marrow back up and induce rapid recovery of white blood cells.

Okay, that makes sense.

We use erythropoietic growth factors, like epiwatin alpha, to stimulate red blood cell production for anemia.

Or we might simply administer iron, B12, folate, or blood transfusions, depending on exactly what blood component the patient is missing.

Before we wrap up, we need to talk about health promotion and synthesis.

We have established that these patients have severely lowered immune resistance.

So how do we handle something as routine as a seasonal flu shot?

The clinical teaching point here is absolute, and Practice Question 5 focuses on this.

A patient receiving anti -neoplastic medications must consult their primary health care provider before receiving any immunizations.

Right.

And more importantly, live virus vaccines are strictly prohibited, and the patient needs to avoid contact with anyone who has recently received a live vaccine.

Their immune system simply cannot handle it.

A live vaccine could cause a fatal infection.

This chapter is intense, but look at how logically it flows when you understand the why.

The foundational pathophysiology, the fact that these drugs attack rapidly dividing cells and cause massive debris, directly dictates every single nursing action.

It really does.

It explains why you are panicked over a platelet count of 50 ,000 before letting a patient brush their teeth.

It explains why you are pushing 3 liters of fluid for a patient on cyclophosphamide to protect their bladder.

You aren't just memorizing random facts, you are learning the mechanism of the machine.

I want to leave you with a final thought to ponder as you continue your studies.

Consider the sheer devastating power of these medications.

We are essentially waging chemical warfare at a microscopic level inside the human body.

We are injecting toxins to destroy a disease, but in doing so, we are demanding that the nurse act as the ultimate shield for the patient's healthy cells.

Wow, yeah.

It makes you realize that as a nurse, you aren't just an administrator of drugs.

You are actively managing, balancing, and protecting a delicate, life -sustaining ecosystem.

How will you look at an IV bag of chemotherapy differently now?

That is a brilliant way to look at it.

You really are the shield.

Well, thank you so much for joining us for this session.

On behalf of the Deep Dive and our last -minute lecture team, we are so incredibly proud of and we wish you the absolute best of luck on your NCLE -X journey.

You are going to be a phenomenal nurse.

Keep studying, keep trusting your clinical judgment, and we will see you next time.